Neurocrine Biosciences to Host R&D Day on December 16

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) will hold its 2025 R&D Day on Tuesday, December 16, 2025 at 12:00 p.m. ET in San Diego. Management will highlight the company’s R&D transformation and its growing neuroscience pipeline and will feature a discussion with key opinion leader John Krystal, M.D. from Yale.

The event will be available via a live webcast on the company’s Investor website, with a replay and the R&D Day presentation posted approximately one hour after the event and archived for about one month.

News Market Reaction

+0.39%

1 alert

+0.39% News Effect

On the day this news was published, NBIX gained 0.39%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

R&D Day date: December 16, 2025 R&D Day time ET: 12:00 p.m. Eastern Time R&D Day time PT: 9:00 a.m. Pacific Time +3 more

6 metrics

R&D Day date December 16, 2025 Scheduled company R&D Day event

R&D Day time ET 12:00 p.m. Eastern Time Start time of R&D Day webcast

R&D Day time PT 9:00 a.m. Pacific Time Local event time in San Diego

Webcast replay delay Approximately one hour Time after event until replay is available

Replay archive length Approximately one month Duration webcast replay remains available

Company history Three decades Time spent applying neuroscience expertise

Market Reality Check

Price: $141.20 Vol: Volume 1,430,071 is 1.47x...

normal vol

$141.20 Last Close

Volume Volume 1,430,071 is 1.47x the 20-day average of 970,020 shares. normal

Technical Shares at $154.99, trading above the 200-day MA of $128.16 and 3.24% below the 52-week high of $160.18.

Peers on Argus

NBIX was down 0.33% with mixed peer moves: UTHR -1.93%, RDY -1.56%, TEVA -1.43%,...

NBIX was down 0.33% with mixed peer moves: UTHR -1.93%, RDY -1.56%, TEVA -1.43%, TAK -0.14%, while VTRS gained 0.91%, suggesting stock-specific rather than broad sector momentum.

Common Catalyst One peer (TEVA) also reported neuroscience-related news, submitting an NDA for a schizophrenia treatment, but overall sector news flow was limited.

Historical Context

5 past events · Latest: Nov 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 20	Product profile review	Positive	+0.7%	Narrative review highlighted INGREZZA’s distinctive VMAT2 inhibitor profile and data strength.
Nov 18	Phase 2 results	Positive	-3.4%	Phase 2 SAVITRI trial of osavampator showed significant MDD benefit versus placebo.
Nov 11	Investor conferences	Neutral	-0.3%	Management scheduled fireside chats at Jefferies and Piper Sandler healthcare conferences.
Nov 10	Trial setback	Negative	-1.8%	Phase 2 NBI-1070770 MDD study failed to meet its primary endpoint against placebo.
Oct 28	Earnings report	Positive	-1.1%	Q3 2025 results showed strong INGREZZA and CRENESSITY sales and reaffirmed guidance.

Pattern Detected

Recent NBIX news has often seen muted or mixed price reactions: positive clinical and commercial updates did not consistently translate into sustained gains, while negative trial data saw modest declines.

Recent Company History

Over the last few months, NBIX reported strong Q3 2025 financials with total net product sales of $790M and reaffirmed INGREZZA guidance, alongside detailed 10‑Q disclosure of $794.9M total revenues and a solid cash position. Clinical updates were mixed: a Phase 2 study of NBI-1070770 in MDD did not meet its primary endpoint, while Phase 2 SAVITRI data for osavampator 1 mg showed statistically significant and clinically meaningful reductions in depression severity. Additional news covered investor conferences and a narrative review highlighting INGREZZA’s distinctive VMAT2 inhibitor profile.

Market Pulse Summary

This announcement schedules NBIX’s 2025 R&D Day on December 16, 2025, signaling an upcoming deep div...

Analysis

This announcement schedules NBIX’s 2025 R&D Day on December 16, 2025, signaling an upcoming deep dive into its neuroscience pipeline and ongoing R&D transformation. In recent months, the company reported strong Q3 2025 financials and mixed clinical outcomes across depression programs. Investors may focus on how this event updates mid‑ to late‑stage assets, clarifies development priorities after the NBI‑1070770 setback, and builds on positive osavampator data and INGREZZA franchise strength.

Key Terms

tardive dyskinesia, chorea, Huntington's disease, classic congenital adrenal hyperplasia, +4 more

8 terms

tardive dyskinesia medical

"includes FDA-approved treatments for tardive dyskinesia, chorea associated..."

A chronic movement disorder marked by repetitive, involuntary motions—often of the face, tongue, or limbs—that can develop after long-term use of certain psychiatric or neurological medications. It matters to investors because the condition creates medical need, regulatory scrutiny, potential for expensive treatments or liability, and can shape the commercial value of drugs in development or on the market; think of it as a persistent side effect that can change a drug’s price tag and sales prospects.

chorea medical

"includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's..."

Chorea is a neurological condition that causes sudden, irregular, involuntary movements—like fragments of a dance you can’t control—that can affect the face, limbs, or trunk. It matters to investors because chorea can drive demand for treatments, influence clinical trial design and regulatory decisions, and signal safety or liability risks for companies developing therapies or diagnostics, all of which affect potential market size and financial outlooks.

Huntington's disease medical

"chorea associated with Huntington's disease, classic congenital adrenal hyperplasia..."

A hereditary brain disorder caused by a faulty gene that progressively damages nerve cells, leading to uncontrollable movements, thinking and mood problems, and a shortened lifespan. It matters to investors because the disease creates a clear medical need and potential market for treatments, so news about clinical trial results, regulatory progress, or drug approvals can strongly move biotech and pharmaceutical stock values. Think of it as a predictable, inherited mechanical flaw in a complex machine that companies are trying to fix.

classic congenital adrenal hyperplasia medical

"chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis*..."

A genetic disorder present at birth in which the adrenal glands cannot make the right balance of hormones, usually because a key enzyme is missing, leading to low stress and salt-regulating hormones and excess sex hormones; it can cause dehydration and abnormal genital development in newborns. Investors care because the condition requires lifelong management, newborn screening and specialized drugs or tests, so advances in therapies, diagnostics or gene treatments can create durable markets and regulatory milestones.

neuroendocrine medical

"for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders."

Neuroendocrine describes cells and processes where the nervous system and the hormone system meet: certain nerve-linked cells release chemical messengers (hormones) into the bloodstream in response to nerve signals, acting like a thermostat wired to both a sensor and a heater. Investors care because neuroendocrine functions are central to a class of diseases and treatments—diagnostics, drugs, and devices aimed at these pathways can drive regulatory milestones, revenue potential, and valuation changes for healthcare companies.

neuropsychiatric medical

"for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders."

Conditions or symptoms that involve both the brain’s biology and a person’s mood, thinking or behavior; they sit at the intersection of neurology and psychiatry. Investors care because neuropsychiatric issues often require specialized drugs, devices or diagnostics, carry distinct regulatory and safety risks, and can affect patient populations and market size — think of them as disorders where hardware (brain circuitry) and software (behavior) problems overlap.

biopharmaceutical technical

"is a leading neuroscience-focused, biopharmaceutical company with a simple purpose..."

A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.

key opinion leader technical

"The event will also feature a discussion with key opinion leader John Krystal, M.D...."

A key opinion leader is an individual whose insights, expertise, or influence significantly shape the opinions and decisions of others within a particular field or community. For investors, they are like trusted guides whose views can impact market trends or perceptions, making their perspectives important to watch. Their influence often stems from experience, reputation, or widespread respect among peers.

AI-generated analysis. Not financial advice.

SAN DIEGO, Dec. 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will hold its 2025 R&D Day on Tuesday, December 16, 2025, at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time) in San Diego.

Neurocrine management will highlight the Company's ongoing R&D transformation and its growing neuroscience pipeline. The event will also feature a discussion with key opinion leader John Krystal, M.D., Professor of Translational Research and Professor of Psychiatry, of Neuroscience, and of Psychology at Yale University.

The live webcast can be accessed here and on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast and the supporting R&D Day presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X and Facebook. (*in collaboration with AbbVie)

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-host-rd-day-on-december-16-302637109.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When is Neurocrine Biosciences' R&D Day 2025 (NBIX) scheduled?

Neurocrine's R&D Day is scheduled for Tuesday, December 16, 2025 at 12:00 p.m. ET.

How can investors watch the Neurocrine (NBIX) R&D Day webcast?

The live webcast is available on Neurocrine's Investor website at neurocrine.com.

Will Neurocrine (NBIX) post a replay of the R&D Day presentation?

Yes. A replay and the supporting presentation will be posted about one hour after the event and archived for approximately one month.

Who will speak at Neurocrine Biosciences' R&D Day on December 16, 2025?

Neurocrine management will present and the program features a discussion with John Krystal, M.D., Professor at Yale.

What topics will Neurocrine (NBIX) cover during the 2025 R&D Day?

The event will highlight the company's ongoing R&D transformation and its expanding neuroscience pipeline.

How long will the Neurocrine R&D Day replay remain online?

The replay and presentation will be archived on the website for about one month.